Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: A retrospective cohort study - 09/04/20
Doi : 10.1016/j.jaad.2020.02.029
Christine E. Jo, BSc a, Jorge R. Georgakopoulos, MD b, Matthew Ladda, BSc c, Arvin Ighani, MD b, Asfandyar Mufti, MD b, Aaron M. Drucker, MD, ScM, FRCPC b, d, Vincent Piguet, MD, PhD, FRCP b, d, Jensen Yeung, MD, FRCPC b, d, e, f, ⁎ 
a Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
b Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
c Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
d Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada
e Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
f Probity Medical Research Inc, Waterloo, Ontario, Canada
∗Correspondence to: Jensen Yeung, MD, FRCPC, Division of Dermatology, Women's College Hospital, 76 Grenville St, Fifth Floor, Toronto, Ontario, Canada, M5S 1B2Division of DermatologyWomen's College Hospital76 Grenville St, Fifth FloorTorontoOntarioM5S 1B2Canada
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Thursday 09 April 2020
| Funding sources: None. |
|
| Disclosure: In the last 3 years, Dr Drucker has served as an investigator and has received research funding from Sanofi and Regeneron; has been a consultant for Sanofi, RTI Health Solutions, Eczema Society of Canada, and Canadian Agency for Drugs and Technology in Health; and has received honoraria from Prime Inc, Spire Learning, CME Outfitters, Eczema Society of Canada, and the Canadian Dermatology Association, and his institution has received educational grants from Sanofi and AbbVie. Dr Piguet has received honoraria or fees for consulting and/or speaking for AbbVie, Almirall, Celgene, Janssen, Novartis, and Pfizer and has received departmental support for Cardiff University from AbbVie, Almirall, Alliance, Beiersdorf UK Ltd, Biotest, Celgene, Dermal, Eli Lilly, Galderma, Genus Pharma, GlobeMicro, Janssen-Cilag, LaRoche-Posay, L'Oréal, LEO Pharma, Meda, Merck Sharp & Dohme, Novartis, Pfizer, Sinclair Pharma, Spirit, Stiefel, Samumed, Thornton Ross, TyPharm, and UCB and for the University of Toronto from Sanofi. Dr Yeung has been a speaker, consultant, and investigator for AbbVie, Allergan, Amgen, Astellas, Boehringer Ingelheim, Celgene, Centocor, Coherus, Dermira, Eli Lilly, Forward, Galderma, GlaxoSmithKline, Janssen, Leo, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Takeda, UCB, Valeant, Xenon. Ms Jo, Dr Georgakopoulos, Mr Ladda, Dr Ighani, and Dr Mufti have no conflicts of interest to declare. |
|
| IRB approval status: Reviewed and approved by the Research Ethics Board at Sunnybrook Health Sciences Centre (205-2018) and Women's College Hospital (2018-0079-E). |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?